- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Biomarker-Driven Lung Cancer | Clinical
Study Underway to Test ALRN-6924 in p53-Mutated Non–Small Cell Lung Cancer
July 02, 2021
A phase 1b trial is currently recruiting patients with advanced p53-mutated non–small cell lung cancer in order to determine the safety and efficacy of ALRN-6924, and reduce chemotherapy toxicity in this patient population.
Adagrasib for KRAS G12C+ Lung Cancer Granted Breakthrough Therapy Designation by FDA
June 25, 2021
The FDA has granted a breakthrough therapy designation from the FDA for patients with advanced non-small cell lung cancer with a KRASG12C mutation following prior systemic treatment.
The Latest Practices for Testing and Treating Lung Adenocarcinoma
June 21, 2021
In an interview with Targeted Oncology, Aaron Lisberg, MD spoke on the importance of molecular testing for patients with lung adenocarcinoma, and provided tips for choosing between immunotherapy and a tyrosine kinase inhibitor.
FDA Grants Fast Track Designation to Bemcentinib/PD-L1 Therapy for AXL+ Advanced/Metastatic NSCLC
June 09, 2021
The FDA has granted fast track designation to bemcentinib in combination with an anti-PD-L1 agent as a potential treatment option for patients with AXL-positive advanced or metastatic non-small cell lung cancer.
CLN-081 Demonstrates Anti-Tumor Activity and Safety in EGFR+ NSCLC
June 04, 2021
Patients with previously treated non–small cell lung cancer harboring EGFR exon 20 insertion mutations showed promising preliminary anti-tumor activity and an acceptable safety profile across all of the doses tested in a phase 1 trial of CLN-081.
Pralsentinib Demonstrates Tolerability and Elicits Durable Responses in RET Fusion-Positive NSCLC
June 04, 2021
In the phase 1/2 ARROW study, pralsentinib was found to be well-tolerated and showed durable responses as treatment of patients with RET fusion-positive non-small cell lung cancer, including those who were not eligible for platinum-based therapy.
Addressing Unmet Needs to Precision Medicine in EGFR Exon 20-Positive NSCLC
June 01, 2021
Joshua K. Sabari, MD, discusses the need for EGFR inhibitors designed specifically to treat patients with EGFR-mutant non–small cell lung cancer and an exon 20 insertion.
FDA Approves Guardant360 Liquid Biopsy as CDx for Sotorasib in NSCLC
June 01, 2021
The FDA has approved Guardant360, a liquid biopsy companion diagnostic for tumor mutation profiling or comprehensive genomic profiling to identify patients with locally advanced or metastatic non-small cell lung cancer who have a KRAS G12C mutation and may benefit from sotorasib.
FDA Approves Sotorasib for KRAS G12C+ Locally Advanced or Metastatic NSCLC
May 28, 2021
The FDA has granted accelerated approval to sotorasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA-approved test, who have received at least one prior systemic therapy.
Twice Daily Poziotinib Helps Lesson Toxicity in EGFR or HER2 exon 20-Positive NSCLC
May 14, 2021
In an interview with Targeted Oncology, Xiuning Le, MD, PhD, discuss the findings from cohort 5 of the ZENITH20 study including the strategy of splitting the dose in half to reduce adverse events associated with poziotinib.